Matthew S Davids, MD, MMSc, is an Assistant Professor of Medicine at Harvard Medical School, Attending Physician in the Lymphoma Program in the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, and Associate Director of the Dana-Farber CLL Center in Boston. He earned his medical degree from Yale University School of Medicine, and served as resident and assistant chief resident in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology with Dana-Farber/Partners CancerCare, and a masters in medical science degree at Havard Medical School. Dr Davids has an active translational research program in CLL, studying BCL2 biology in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of the BCL2 inhibitor venetoclax and utilizing checkpoint blockade to enhance antitumor immunity in patients with hematologic malignancies who relapse post-allogeneic hematopoietic cell transplantation. Dr Davids has authored several peer-reviewed articles that have been published in American Journal of Hematology, Future Oncology, and Journal of Clinical Oncology. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association of Cancer Research, and European Hematology Assocation.